UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 297

Sortiert nach

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3287-3296

2012

Volltextzugriff (PDF)

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-06, Vol.36 (18), p.1813-1822

2018

Volltextzugriff (PDF)

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Journal of clinical oncology, 2020-06, Vol.38 (16), p.1824-1835

2020

Volltextzugriff (PDF)

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4105-4114

2013

Volltextzugriff (PDF)

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Journal of clinical oncology, 2019-06, Vol.37 (18), p.1558-1565

2019

Volltextzugriff (PDF)

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer

Cancer, 2023-05, Vol.129 (9), p.1319-1350

2023

Volltextzugriff (PDF)

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Clinical cancer research, 2018-06, Vol.24 (12), p.2771-2779

2018

Volltextzugriff (PDF)

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2019-06, Vol.14 (6), p.1021-1031

2019

Volltextzugriff (PDF)

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2312-2318

2011

Volltextzugriff (PDF)

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-09, Vol.27 (26), p.4274-4280

2009

Volltextzugriff (PDF)

Phase II study of gefitinib in patients with advanced salivary gland cancers

Head & neck, 2015-05, Vol.37 (5), p.644-649

2015

Volltextzugriff (PDF)

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

Clinical cancer research, 2012-04, Vol.18 (8), p.2269-2277

2012

Volltextzugriff (PDF)

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

JNCI : Journal of the National Cancer Institute, 2012-02, Vol.104 (3), p.228-239

2012

Volltextzugriff (PDF)

Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival

Radiotherapy and oncology, 2015-05, Vol.115 (2), p.257-263

2015

Volltextzugriff (PDF)

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Clinical cancer research, 2015-06, Vol.21 (11), p.2462-2470

2015

Volltextzugriff (PDF)

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Nature medicine, 2023-01, Vol.29 (1), p.104-114

2023

Volltextzugriff (PDF)

Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome

Journal of thoracic oncology, 2011-10, Vol.6 (10), p.1763-1773

2011

Volltextzugriff (PDF)

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

ESMO open, 2020-10, Vol.5 (5), p.e000799-e000799, Article e000799

2020

Volltextzugriff (PDF)

The BATTLE trial: personalizing therapy for lung cancer

Cancer discovery, 2011-06, Vol.1 (1), p.44-53

2011

Volltextzugriff (PDF)

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4609-4615

2010

Volltextzugriff (PDF)

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2015-06, Vol.92 (2), p.317-324

2015

Volltextzugriff (PDF)

Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial

Journal of thoracic oncology, 2013-04, Vol.8 (4), p.436-442

2013

Volltextzugriff (PDF)

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1938-1949

2010

Volltextzugriff (PDF)

Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis

Immunotherapy, 2023-03, Vol.15 (4), p.293-309

2023

Volltextzugriff (PDF)

1 – 25 von 297

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(263)
Mit Volltextzugriff
(248)

Publikationsform

Artikel
(276)
Buchkapitel
(20)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(171)
Science & Technology
(156)
Life Sciences & Biomedicine
(155)
Oncology
(151)
Female
(134)
Middle Aged
(118)
Aged
(107)
Adult
(101)
Male
(66)
Lung Neoplasms - Drug Therapy
(53)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(49)
Breast Neoplasms - Drug Therapy
(46)
Biological And Medical Sciences
(43)
Medical Sciences
(43)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(39)
Neoplasm Metastasis
(37)
Chemotherapy
(36)
Tumors
(31)
Aged, 80 And Over
(30)
Prognosis
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

Phase II study of gefitinib in patients with advanced salivary gland cancers

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

The BATTLE trial: personalizing therapy for lung cancer

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer

Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis

Suchergebnisse filtern